“Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s163. doi:10.25251/skin.7.supp.163.